Cargando…
Effectiveness of immunological agents in non‐small cell lung cancer
BACKGROUND AND AIM: Non‐small cell lung cancer (NSCLC) continues to claim millions of lives worldwide. Although its poor prognosis is largely attributed to the lack of adequate and precise detection technologies, cancer cells’ suppression of the immune system adds on to the difficulty of identifying...
Autores principales: | Rekulapelli, Akhil, E. Flausino, Lucas, Iyer, Gayatri, Balkrishnan, Rajesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981233/ https://www.ncbi.nlm.nih.gov/pubmed/36289059 http://dx.doi.org/10.1002/cnr2.1739 |
Ejemplares similares
-
Racial and Treatment Center Differences on Time to Treatment Initiation for Nonsmall Cell Lung Cancer Patients Receiving Radiation Therapy As an Initial Treatment
por: Rekulapelli, Akhil, et al.
Publicado: (2022) -
Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A Medicare SEER cohort analysis
por: Balkrishnan, Rajesh, et al.
Publicado: (2021) -
Small molecules as theranostic agents in cancer immunology
por: Li, Jindian, et al.
Publicado: (2019) -
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018) -
Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer
por: Jiang, Li, et al.
Publicado: (2022)